We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Tristel Plc | TSTL | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 462.50 | 08:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 462.50 | 462.50 | 462.50 | 462.50 |
| Industry Sector |
|---|
| HEALTH CARE EQUIPMENT & SERVICES |
| Announcement Date | Type | Currency | Dividend Amount | Ex Date | Record Date | Payment Date |
|---|---|---|---|---|---|---|
| 26/02/2024 | Interim | GBP | 0.0524 | 21/03/2024 | 22/03/2024 | 12/04/2024 |
| 16/10/2023 | Final | GBP | 0.0788 | 23/11/2023 | 24/11/2023 | 22/12/2023 |
| 20/02/2023 | Interim | GBP | 0.0262 | 16/03/2023 | 17/03/2023 | 11/04/2023 |
| 18/07/2022 | Final | GBP | 0.0393 | 17/11/2022 | 18/11/2022 | 16/12/2022 |
| 18/07/2022 | Special | GBP | 0.03 | 28/07/2022 | 29/07/2022 | 10/08/2022 |
| 21/02/2022 | Interim | GBP | 0.0262 | 07/04/2022 | 08/04/2022 | 29/04/2022 |
| 26/04/2021 | Final | GBP | 0.0393 | 18/11/2021 | 19/11/2021 | 16/12/2021 |
| 22/02/2021 | Interim | GBP | 0.0262 | 08/04/2021 | 09/04/2021 | 30/04/2021 |
| 19/10/2020 | Final | GBP | 0.0384 | 19/11/2020 | 20/11/2020 | 18/12/2020 |
| 24/02/2020 | Interim | GBP | 0.0234 | 26/03/2020 | 27/03/2020 | 30/04/2020 |
| 16/10/2019 | Final | GBP | 0.035 | 21/11/2019 | 22/11/2019 | 20/12/2019 |
| Top Posts |
|---|
Posted at 22/4/2024 08:14 by melton john A while since I owned TSTL Piedro but still on mmy watch list. I must have missed the Clorox deal you refer to. Do you have a link please. |
Posted at 07/4/2024 20:33 by loafofbread If he was happy to splash out up to £2M on this deal, I would think £4M for the lot would be an absolute steal!23 March 2020 TRISTEL plc ("Tristel" or the "Company") Know-How License and Product Supply Agreement with Byotrol plc ("Byotrol") Tristel plc (AIM: TSTL), the manufacturer of infection prevention and contamination control products announces that it has entered into a know-how licence and commercial collaboration with Byotrol ("Agreement"). The Agreement relates to the joint development of a biocidal formulation and Byotrol's development of two additional biocidal products and formulations that will be supplied and licensed to Tristel. Jointly developed formulation This formulation will create a unique surface disinfectant product for hospitals by combining the two companies' core technologies. The formulation combines Tristel's chlorine dioxide chemistry, which is sporicidal meaning that it has the highest level of disinfection efficacy, with ACTIZONE, a Solvay S.A. technology developed in collaboration with Byotrol and which enables a disinfectant to have long-lasting efficacy on a surface for an 8-hour period after first application. Tristel will incorporate the jointly developed formulation in several packaging formats under the family name "Tristel8". These products will be unique worldwide in combining sporicidal efficacy with residual disinfection efficacy. Additional biocidal products In addition, Byotrol will licence two biocidal formulations to Tristel for incorporation in its surface disinfectants range which is branded Cache. Cache represents a novel approach to today's very relevant issues of hospital hygiene and environmental concern. The Byotrol products and formulations give Tristel access to intermediate level disinfectants that are effective against bacteria, viruses and yeasts in accordance with the requirements of European Test Norms. The disinfectants will be for use in hospitals and will conform with the requirements of the European Biocidal Products Registration (BPR), and the United Kingdom equivalent that will come into force post Brexit. As this legislation is implemented throughout the United Kingdom and Europe during the coming years various active ingredients that are commonly incorporated in hospital grade disinfectants will be withdrawn from use. Tristel has previously incorporated some of these active ingredients in the intermediate level disinfectants that it presents to hospitals alongside its high-performance chlorine dioxide disinfectants. The Agreement will ensure that Tristel will continue to comply fully with the future regulatory environment that will govern the manufacture and sale of disinfectants for surface disinfection. Commercial arrangements Tristel will manufacture all the products deriving from the formulations, whilst Byotrol will supply the ACTIZONE material. Byotrol will receive payments from Tristel based upon volumes manufactured and product sales. Tristel will be responsible for branding and global sales and marketing through its thirteen subsidiaries and 35 international distributors. We expect sales of these new products to commence in the next financial year. Commenting on the collaboration and current trading conditions, Paul Swinney, Chief Executive of Tristel, said: "Tristel and Byotrol are both specialist infection prevention companies, and in recent years we have forged a close working relationship. This collaboration holds great promise for both businesses. For Tristel it provides us a future-proofed intermediate grade disinfectant that we will incorporate into our hospital surface disinfectants product portfolio. "The second key element of the arrangement is that we will combine a sporicidal high-performance disinfectant, which has an unrivalled kill time, with long-lasting disinfection activity that is proven to last for eight hours in accordance with PAS2424, a test developed with BSI and currently under detailed review by the EU for EN status. This combination of technologies creates a ground-breaking proposition. It is akin to clearing a crowd out of a stadium in 30 seconds and then keeping the doors closed to stop anyone re-entering. We must caution, however, that adoption of new infection prevention technology is often slow in healthcare, as both our companies know from first-hand experience. |
Posted at 07/4/2024 17:04 by james188 I struggle to think of a worse move for TSTL to make than to acquire Byotrol. It has all the rights that it needs and has much more important things to concentrate on. |
Posted at 28/2/2024 11:56 by z1co Tristel tipped to double revenue as it targets the North American marketBy John Foster 26th February 2024 Tristel [LON:TSTL] the AIM-listed manufacturer of antibacterial cleaning products published its half-year results today (26th February). The Snailwell-based company specialises in infection prevention. Tristel develops products and solutions to help prevent the spread of harmful microbes, particularly in healthcare settings. Their main focus is on disinfecting medical devices and offers various products, like wipes and solutions, that healthcare professionals can use to disinfect reusable medical devices at the point of use, eliminating the need for sending them to a central sterilization department. The firm also offers products for disinfecting surfaces including large surfaces like floors and walls and the company says that its products are formulated to be effective against a broad spectrum of microorganisms, including bacteria, viruses, and spores. Tristel’s technology utilizes a proprietary chlorine dioxide chemistry that they claim is unique in its effectiveness and safety compared to traditional disinfectants. Back in July 2023 The Armchair Trader noted that Tristel was one on the UK’s top five performing healthcare stocks. In July it was trading at 360p, today Tristel opened at 499.6p climbing to 503.32p on release of its results, up 39.8%. Over one-year the share price is up 45.9% and up 73.6% over five-years. The company saw its revenue grow 20% year-on-year to GBP20.9m in the six-months to the end of December 2023 with overseas sales up 13% to GBP12.7m and earnings up 21% to GBP4.7m Tristel profits and dividends up This led to reported profits before tax of GBP3.4m which were up y-o-y by 44% and the company doubled the interim dividend to 5.25p per share. The company has no debt and cash in the bank of GBP10.8m. Paul Swinney, CEO, who announced his retirement at the end of the year, said in a statement this morning: “I am thrilled that the company continues to thrive and grow, with a pipeline of new product launches planned for the near term […] This six-month period represents the highest sales and profit performance that the company has experienced in its thirty-year history, including during the early COVID era when demand for our products was unprecedented.&rdquo The company experienced strong growth in 2019-20 during the coronavirus pandemic, and as previously reported, was on the verge of entering the North American market, getting the greenlight from US and Canadian regulators to start marketing its products in the region. Sweeney said: “Our North American business strategy focuses on entering each of the key market segments that we dominate in other countries. Ultrasound is our largest segment globally in terms of disinfection procedure events, followed by ENT, cardiology and airway management. Ophthalmology is a very significant global opportunity in terms of disinfection events, but in all countries very few procedures that should be performed with a high-level disinfectant in fact are.” The company is tipped to double its revenue in the next five years, with its North American strategy driving growth, and in the period reported saw the first manufacture and launch of Tristel ULT in the United States, a disinfection product that is used on ultrasound units, which also was cleared by regulators for distribution in Canada. The company already has clearance to sell its Tristel OHP product in Canada, a disinfectant for ophthalmic devices, and Tristel is in the process of submitting Tristel OHP to the US regulators. North American manufacturing plant The company has established a manufacturing facility in the United States, in New Jersey, with Parker Technologies and Swinney noted that during the first ten weeks of activity in North America, Tristel’s revenue and royalty was GBP46,000. He said: “We are very encouraged by this positive start.” Bridgewise rates Tristel as ‘Outperform.&r The simplicity and utility of Tristel’s products make regulatory clearance – often a high hurdle for other biotech companies – a great deal simpler, and the North American healthcare market is a vast and profitable market opportunity that could be transformational for the Cambridgeshire healthcare company. |
Posted at 27/2/2024 17:40 by z1co Yes we already know that 74tom.Your post is a very subtle deramp suggesting that you have sold out and are waiting for a suitable re-entry. Parker Laboratories plans an extensive marketing and trade show programme throughout 2024 and is in the process of expanding its salesforce in order to capitalise on the potential that Tristel ULT represents. The company will provide more info regarding the US and Canadian revenue and the royalty TSTL will receive in their next trading update for the 6 months to June. TSTL has always had a high rating even during and after the covid period when i last sold the shares. The company has in 2024 entered a new phase of explosive growth which is likely to remain for many years. |
Posted at 26/2/2024 17:40 by z1co Good article by the arm chair trader:Tristel tipped to double revenue as it targets the North American market By John Foster 26th February 2024 Tristel [LON:TSTL] the AIM-listed manufacturer of antibacterial cleaning products published its half-year results today (26th February). The Snailwell-based company specialises in infection prevention. Tristel develops products and solutions to help prevent the spread of harmful microbes, particularly in healthcare settings. Their main focus is on disinfecting medical devices and offers various products, like wipes and solutions, that healthcare professionals can use to disinfect reusable medical devices at the point of use, eliminating the need for sending them to a central sterilization department. The firm also offers products for disinfecting surfaces including large surfaces like floors and walls and the company says that its products are formulated to be effective against a broad spectrum of microorganisms, including bacteria, viruses, and spores. Tristel’s technology utilizes a proprietary chlorine dioxide chemistry that they claim is unique in its effectiveness and safety compared to traditional disinfectants. Back in July 2023 The Armchair Trader noted that Tristel was one on the UK’s top five performing healthcare stocks. In July it was trading at 360p, today Tristel opened at 499.6p climbing to 503.32p on release of its results, up 39.8%. Over one-year the share price is up 45.9% and up 73.6% over five-years. The company saw its revenue grow 20% year-on-year to GBP20.9m in the six-months to the end of December 2023 with overseas sales up 13% to GBP12.7m and earnings up 21% to GBP4.7m Tristel profits and dividends up This led to reported profits before tax of GBP3.4m which were up y-o-y by 44% and the company doubled the interim dividend to 5.25p per share. The company has no debt and cash in the bank of GBP10.8m. Paul Swinney, CEO, who announced his retirement at the end of the year, said in a statement this morning: “I am thrilled that the company continues to thrive and grow, with a pipeline of new product launches planned for the near term […] This six-month period represents the highest sales and profit performance that the company has experienced in its thirty-year history, including during the early COVID era when demand for our products was unprecedented.&rdquo The company experienced strong growth in 2019-20 during the coronavirus pandemic, and as previously reported, was on the verge of entering the North American market, getting the greenlight from US and Canadian regulators to start marketing its products in the region. Sweeney said: “Our North American business strategy focuses on entering each of the key market segments that we dominate in other countries. Ultrasound is our largest segment globally in terms of disinfection procedure events, followed by ENT, cardiology and airway management. Ophthalmology is a very significant global opportunity in terms of disinfection events, but in all countries very few procedures that should be performed with a high-level disinfectant in fact are.” The company is tipped to double its revenue in the next five years, with its North American strategy driving growth, and in the period reported saw the first manufacture and launch of Tristel ULT in the United States, a disinfection product that is used on ultrasound units, which also was cleared by regulators for distribution in Canada. The company already has clearance to sell its Tristel OHP product in Canada, a disinfectant for ophthalmic devices, and Tristel is in the process of submitting Tristel OHP to the US regulators. North American manufacturing plant The company has established a manufacturing facility in the United States, in New Jersey, with Parker Technologies and Swinney noted that during the first ten weeks of activity in North America, Tristel’s revenue and royalty was GBP46,000. He said: “We are very encouraged by this positive start.” Bridgewise rates Tristel as ‘Outperform.&r The simplicity and utility of Tristel’s products make regulatory clearance – often a high hurdle for other biotech companies – a great deal simpler, and the North American healthcare market is a vast and profitable market opportunity that could be transformational for the Cambridgeshire healthcare company. |
Posted at 26/2/2024 16:05 by z1co The management today have increased the interim dividend by 100% to 5.24p , this is a clear sign that they are very confident that the company will keep growing it's revenue , PBT , EPS and also be very cash generative.Very rare that a company increases it's dividend this much unless they know that their business will trade very strongly and ahead of expectations for the foreseeable future. In the past companies that have significantly increased their dividends , their share price has also performed very strongly. |
Posted at 26/2/2024 15:10 by 74tom Presentation certainly didn't set the world on fire, it felt a bit as though the CFO was hung out to dry by the CEO, who sat next to her but only answered one question (and the answer was by far the most comprehensive & confident of the meeting). Unsure why the outgoing CEO felt the need to be a bystander, especially after such positive results.Valuation looks challenging to me, (even assuming for a full year beat and 14p EPS, they are on 33x FY24 P/E) especially if they want to be treated as a growth company but insist on paying out a material proportion of their EPS as a dividend. Wouldn't shareholders prefer them to invest in their R&D resource so they can get products to market faster? Nanosonics also reported today on the ASX , missed expectations & shares fell 15% to multi year lows. Their revenues are double TSTL, but due to them spending ~£16m PA on R&D their reported PBT fell to below TSTL. Market cap down to £410m with £60m cash, so on an EV/Sales basis they are now around 20% cheaper than TSTL vs level pegging on Friday. Quite a divergence, which is understandable based on today's results alone, but seems to underestimate their installed base on 30k machines in the US. Either way, a quality company & long term success story, but based on today's call I'd be concerned that the outgoing CEO will be difficult to replace and hence the 34x rating offers next to no margin of safety. |
Posted at 26/2/2024 07:58 by zimbtrader Tristel plc (AIM: TSTL), the manufacturer of infection prevention products utilising proprietary chlorine dioxide technology, announces its interim results for the six months to 31 December 2023, exceeding internal growth targets by delivering 20% revenue growth and 44% growth in pre-tax profits. The Company also announces a doubling of its interim dividend payment.The Company's core business is the sale to hospitals of its proprietary chlorine dioxide chemistry used for the decontamination of medical devices under the Tristel brand, and for the sporicidal disinfection of environmental surfaces under the Cache brand. Financial highlights· Revenue up 20% to a record £20.9m (2022: £17.5m)· Overseas sales up 13% to £12.7m (2022: £11.2m)· Reported EBITDA up 21% to £4.7m (2022: £3.9m)· Adjusted* EBITDA up 18% to £5.4m (2022: £4.6m)· Reported profit before tax up 44% to £3.4m (2022: £2.4m)· Adjusted* profit before tax up 34% to £4.1m (2022: £3.1m)· Reported EPS up 104% to 6.50p (2022: 3.19p)· Adjusted* EPS of 8.68p up 87% (2022: 4.65p)· Doubling of interim dividend to 5.24p per share (2022: 2.62p)· No debt and cash of £10.8m (2022: £8.4m)*Adjusted for share-based payments of £0.7m (2022: £0.7m)Operational highlights· First manufacture and launch of Tristel ULT into the United States ultrasound market· Approval of Tristel ULT by Health Canada post-period end· UK & EU Medical Device Regulation reviews of Cache Tank and Capsule successfully concluded and positive recommendation for UKCA and MDR certification made post-period end |
Posted at 05/1/2024 07:20 by piedro My Portfolio: Year In Review 2023I recap how each of my shares performed during 2023, including System1, Tristel, Bioventix and Mountview Estates. 02 January 2024 By Maynard Paton 2) Tristel (TSTL) "... December’s AGM also announced TSTL’s long-time chief exec is to retire this year. Deciding to retire when the exciting US potential all lies ahead may seem odd, but I believe TSTL’s ambition to become a “global market leader” demands skills beyond the present board given the protracted FDA saga. I would not be surprised if the finance director, who is married to the chief exec, decides to leave as well. A pair of US healthcare executives could be welcome replacements. ... - well said Maynard. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
